Researchers shed new light on how remylination fails in multiple sclerosis. The study reports a drug, currently being studied as a cancer therapy, can alter the key signaling cascades that result in demylination associated with MS.
from Neuroscience News https://ift.tt/3di2VzN
Comments
Post a Comment